Eledon Pharmaceuticals (ELDN) Shares Outstanding: History & Chart

Eledon Pharmaceuticals, Inc.(ELDN)

Biotechnology · Irvine, CA

$2.51+0.00 (+0.20%)

Delayed quote: Oct 6, 2026, 11:14 AM EDT

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.

Irvine, CA

33 employees

eledon.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: David-Alexandre C. Gros

View full financials

Latest FMP share-count observation

Shares outstanding

77,187,800

Float shares

70,743,412

Source: FMP shares-float. FMP feed updated 2026-10-06 04:49:00 (timezone not supplied). The feed does not specify the effective date of this share count.

Shares outstanding measure the share count in the provider observation. Basic and diluted weighted averages below are EPS calculation inputs. Differences between these counts do not measure new issuance or buybacks.

Weighted-average shares by quarterly statement

FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.

Statement period	Period end	Weighted average basic shares	Weighted average diluted shares
Q2 FY2026	2026-06-30	113,631,565	113,631,565
Q1 FY2026	2026-03-31	112,424,211	112,424,211
Q4 FY2025	2025-12-31	75,430,033	75,430,033
Q3 FY2025	2025-09-30	77,156,068	77,156,068
Q2 FY2025	2025-06-30	77,156,068	77,156,068
Q1 FY2025	2025-03-31	77,126,763	77,126,763
Q4 FY2024	2024-12-31	59,789,275	59,789,275
Q3 FY2024	2024-09-30	51,945,920	55,478,342
Q2 FY2024	2024-06-30

Weighted-average shares by annual statement

FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.

Statement period	Period end	Weighted average basic shares	Weighted average diluted shares
2025	2025-12-31	81,836,246	81,836,246
2024	2024-12-31	48,543,000	48,543,787
2023	2023-12-31	24,619,197	24,619,197
2022	2022-12-31	14,285,254	14,285,254
2021	2021-12-31	14,819,582	14,819,582
2020	2020-12-31	15,160,397	15,160,397
2019	2019-12-31	11,799,450	11,799,450
2018	2018-12-31	9,005,346	9,005,346
2017	2017-12-31	4,677,606

Shares Outstanding: 77,187,800

Latest FMP share-count observation

ELDN Weighted Average Basic Shares

ELDN Weighted Average Diluted Shares

Weighted-average shares by quarterly statement

Weighted-average shares by annual statement